Elenco degli articoli con argomento «carcinoma basocellulare»
Dermatologia05 feb 2024
Final analysis of phase II results with cemiplimab
Metastatic basal cell carcinoma (mBCC) is a rare condition with no effective second-line treatment options
24 gen 2024
Il carcinoma al viso, Paola Ferrari come si interviene
La giornalista Paola Ferrari ha parlato di un nuovo basalioma, un carcinoma al viso, che l'aveva già costretta a un primo intervento chirurgico. Si opererà di nuovo. Di cosa si tratta e come si cura
05 set 2022
Curettage vs. cryosurgery for superficial basal cell carcinoma
Basal cell carcinoma (BCC) is the most common cancer in the world and has a rising incidence.
11 lug 2022
Line-Field Confocal Optical Coherence
Diagnosing clinically unclear basal cell carcinomas (BCCs) can be challenging.
16 mag 2022
Curettage versus cryosurgery for superficial basal cell carcinoma
Basal cell carcinoma (BCC) is the most common cancer in the world and has a rising incidence.
10 mag 2022
BCC AVANZATO
Studio osservazionale retrospettivo e prospettico sui pazienti affetti da carcinoma basocellulare avanzato
29 apr 2022
Unusual dermoscopic patterns
Basal cell carcinoma can simulate melanoma and specific dermoscopic criteria have not yet been defined in a large cohort
28 feb 2022
How to spot a basosquamous carcinoma
Basosquamous carcinoma (BSC) is a relatively rare type of neoplasm originating from basal cell carcinoma with features of squamous differentiation.
24 gen 2022
Position paper on a simplified histopathological classification of basal cell carcinoma
Histopathological classification of basal cell carcinoma (BCC) has important prognostic and therapeutic implications, but reproducibility of BCC subtyping among dermatopathologists is poor.
26 ago 2021
Position statement on Classification of Basal Cell Carcinomas
No simple staging system has emerged for basal cell carcinomas (BCCs)
26 ago 2021
Position statement on classification of basal cell carcinomas
No simple classification system has emerged for 'advanced basal cell carcinomas', and more generally for all difficult-to-treat BCCs
13 apr 2021
Clinical and Dermoscopic Factors
Infiltrative basal cell carcinoma (BCC) has a higher risk for post-surgical recurrence as compared to the most common low-aggressive superficial and nodular BCC.
20 ott 2020
Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis
Is exposure to topical calcineurin inhibitors among adult patients with atopic dermatitis associated with increased keratinocyte carcinoma risk?
06 ott 2020
Systematic Review of Mohs Micrographic Surgery in Children
Identifying Challenges and Practical Considerations for Successful Application
18 mag 2020
Metformin as an Adjuvant to Photodynamic Therapy in Resistant Basal Cell Carcinoma Cells
Photodynamic Therapy (PDT) with methyl-aminolevulinate (MAL-PDT) is being used for the treatment of Basal Cell Carcinoma (BCC), although resistant cells may appear.
26 apr 2020
Quality‐of‐life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas
patient‐reported outcomes from the MIKIE study
06 apr 2020
Presurgical evaluation of basal cell carcinoma using combined reflectance confocal microscopy–optical coherence tomography
A prospective study
17 dic 2019
Sex-stratified polygenic risk score identifies individuals at increased risk of basal cell carcinoma
The incidence of basal cell carcinoma (BCC) is higher among men than women.
17 set 2019
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of Research and Treatment of Cancer collaborated to develop recommendations on diagnosis and treatment of BCC. A new classification into 'easy-to-treat (common) BCC and 'difficult-to-treat' BCC is proposed.
22 mag 2019
Metastasis of cutaneous squamous cell carcinoma in organ transplant recipients and the immunocompetent population: is there a difference? a systematic
Organ transplant recipients (OTR) have a higher risk of developing cutaneous squamous cell carcinoma (cSCC) compared to the immunocompetent population. Immunosuppression is often stated as a risk factor for metastasis. However, evidence for this is scarce. Objectives